Baird analyst David Rescott raised the firm’s price target on Merit Medical (MMSI) to $108 from $103 and keeps an Outperform rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Hold Rating for Merit Medical Systems Due to Pending Long-term Data and Pricing Challenges for WRAPSODY Stent
- Merit Medical price target lowered to $93 from $104 at Canaccord
- Merit Medical price target lowered to $95 from $103 at Wells Fargo
- Merit Medical Systems: Strategic Adjustments and Growth Potential Justify Buy Rating
- Closing Bell Movers: Applied Materials down 4% after earnings and guidance